GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » EV-to-Revenue

Acarix AB (OSTO:ACARIX) EV-to-Revenue : 44.92 (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Acarix AB's enterprise value is kr193.13 Mil. Acarix AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr4.30 Mil. Therefore, Acarix AB's EV-to-Revenue for today is 44.92.

The historical rank and industry rank for Acarix AB's EV-to-Revenue or its related term are showing as below:

OSTO:ACARIX' s EV-to-Revenue Range Over the Past 10 Years
Min: -16.03   Med: 24.49   Max: 1952.09
Current: 41.08

During the past 10 years, the highest EV-to-Revenue of Acarix AB was 1952.09. The lowest was -16.03. And the median was 24.49.

OSTO:ACARIX's EV-to-Revenue is ranked worse than
92.89% of 830 companies
in the Medical Devices & Instruments industry
Industry Median: 3.265 vs OSTO:ACARIX: 41.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Acarix AB's stock price is kr0.3245. Acarix AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.01. Therefore, Acarix AB's PS Ratio for today is 46.36.


Acarix AB EV-to-Revenue Historical Data

The historical data trend for Acarix AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB EV-to-Revenue Chart

Acarix AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.99 48.13 54.37 11.24 17.51

Acarix AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.24 27.00 22.39 17.51 -

Competitive Comparison of Acarix AB's EV-to-Revenue

For the Medical Devices subindustry, Acarix AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acarix AB's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Acarix AB's EV-to-Revenue falls into.



Acarix AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Acarix AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=193.132/4.299
=44.92

Acarix AB's current Enterprise Value is kr193.13 Mil.
Acarix AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acarix AB  (OSTO:ACARIX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Acarix AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.3245/0.007
=46.36

Acarix AB's share price for today is kr0.3245.
Acarix AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acarix AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acarix AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acarix AB (OSTO:ACARIX) Business Description

Traded in Other Exchanges
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines